Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Myeloma more likely to go untreated in dual Medicare-Medicaid recipients

Fakhri B et al. Clin Lymphoma Myeloma Leuk. Mar 2018;18(3):219-24.

Key clinical point: Older patients, African Americans, and low-income patients may be less likely to receive multiple myeloma treatment.

Major finding: Factors significantly associated with no systemic treatment included older age (adjusted odds ratio, 1.07 per year), African American descent (aOR, 1.26), and dual Medicare-Medicaid enrollment (aOR, 1.21).

Study details: A retrospective cohort analysis including data on 3,814 patients with active multiple myeloma in the Surveillance, Epidemiology, and End Results–Medicare database from 2007 to 2011.

Disclosures: The research was supported by the National Cancer Institute. The investigators reported having no financial disclosures.

Source: Fakhri B et al. Clin Lymphoma Myeloma Leuk. Mar 2018;18(3):219-24.

Read the article.

Citation:

Fakhri B et al. Clin Lymphoma Myeloma Leuk. Mar 2018;18(3):219-24.

This Week's Must Reads

Atovaquone associated with increased nocardiosis risk, Molina A et al. Acute Leukemia Forum 2018, Poster Session.

Add-on ibrutinib boosted response in relapsed multiple myeloma, Chari A et al. Leuk Lymphoma. 2018 Apr 4. doi: 10.1080/10428194.2018.1443337.

Adding statin boosted AML response rate, Advani AS et al. Leuk Res. 2018 Apr;67:17-20.

Venetoclax is effective in CLL that relapses after idelalisib, , Coutre S et al. Blood. 2018;131(15):1704-11

Pembrolizumab after cytarabine boosts AML response, Zeidner J et al. Acute Leukemia Forum 2018, Poster Session.

Must Reads in Multiple Myeloma

Add-on ibrutinib boosted response in relapsed multiple myeloma, Chari A et al. Leuk Lymphoma. 2018 Apr 4. doi: 10.1080/10428194.2018.1443337.

Myeloma more likely to go untreated in dual Medicare-Medicaid recipients, Fakhri B et al. Clin Lymphoma Myeloma Leuk. Mar 2018;18(3):219-24.

In myeloma, go for a third transplant, Garderet L et al. Biol Blood Marrow Transplant. 2018 Feb 3. doi: 10.1016/j.bbmt.2018.01.035

Cochrane on Bisphosphonates in Multiple Myeloma, Cochrane; 2017 Dec 18; Mhaskar, Kumar, et al

VDT PACE-Like Therapy for Relapsed/Refractory MM, Am J Hematol; ePub 2017 Nov 10; Lakshman, et al